

Highlights of This Issue 5159

SPECIAL FEATURES

CCR Translations

- 5161** Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
Martin Felices and Jeffrey S. Miller
See related article, p. 5211

- 5164** Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity
Carter M. Suryadevara, Katherine A. Riccione, and John H. Sampson
See related article, p. 5265

CCR Perspectives in Regulatory Science and Policy

- 5167** Statistical Considerations in Evaluating a Biosimilar Product in an Oncology Clinical Study
Kun He, Huanyu Chen, Thomas Gwise, Sandra Casak, Steven Lemery, Patricia Keegan, Richard Pazdur, and Rajeshwari Sridhara

CCR Drug Updates

- 5171** FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
Erin Larkins, Gideon M. Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms, Stacy Shord, Jingyu Yu, Hong Zhao, Gina Davis, Amy E. McKee, Patricia Keegan, and Richard Pazdur
- 5177** Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Ferdinandos Skoulidis and Vassiliki A. Papadimitrakopoulou

Molecular Pathways

- 5183** Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake, William C. Dougall, John J. Miles, Michele W.L. Teng, and Mark J. Smyth

Reviews

- 5189** NAD⁺ Kinase as a Therapeutic Target in Cancer
Philip M. Tedeschi, Nitu Bansal, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto, and Joseph R. Bertino
- 5196** Imaging Tumor Metabolism to Assess Disease Progression and Treatment Response
Kerstin N. Timm, Brett W.C. Kennedy, and Kevin M. Brindle

CLINICAL TRIAL BRIEF REPORT

- 5204** An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, Siva Rama Prasad Kambhampati, Shande Tang, Dmitri Grebennik, John Sae Wook Kauh, Heinz-Josef Lenz, Keith T. Flaherty, F. Stephen Hodi, Donald P. Lawrence, and Jedd D. Wolchok

CANCER THERAPY: CLINICAL


- 5211** Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
 Mattias Carlsten, Neha Korde, Ritesh Kotecha, Robert Reger, Simona Bor, Dickran Kazandjian, Ola Landgren, and Richard W. Childs
See related commentary, p. 5161
- 5223** DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
Xin Li, Yingying Cui, Zhenchang Sun, Lei Zhang, Ling Li, Xinhua Wang, Jingjing Wu, Xiaorui Fu, Wang Ma, Xudong Zhang, Yu Chang, Feifei Nan, Wencai Li, Liping Su, Jinghua Wang, Hongwei Xue, and Mingzhi Zhang
- 5229** Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Sumita Trivedi, Raghvendra M. Srivastava, Fernando Concha-Benavente, Soldano Ferrone, Tatiana M. Garcia-Bates, Jing Li, and Robert L. Ferris



Table of Contents

5238 Loss of *ARID1A* Activates *ANXA1*, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohé, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiropoulos, and René Bernards

PERSONALIZED MEDICINE AND IMAGING

5249 Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients

Judith S. Brand, Elham Hedayati, Keith Humphreys, Jonas F. Ludvigsson, Anna L.V. Johansson, Jonas Bergh, Per Hall, and Kamila Czene

5256 Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI

Ke Nie, Liming Shi, Qin Chen, Xi Hu, Salma K. Jabbour, Ning Yue, Tianye Niu, and Xiaonan Sun

CANCER THERAPY: PRECLINICAL

5265 Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy

Ji Young Yoo, Alena Cristina Jaime-Ramirez, Chelsea Bolyard, Hongsheng Dai, Tejaswini Nallanagulagari, Jeffrey Wojton, Brian S. Hurwitz, Theresa Relation, Tae Jin Lee, Michael T. Lotze, Jun-Ge Yu, Jianying Zhang, Carlo M. Croce, Jianhua Yu, Michael A. Caligiuri, Matthew Old, and Balveen Kaur
See related commentary, p. 5164

5277 Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity

Koji Munakata, Mamoru Uemura, Shinji Tanaka, Kenji Kawai, Tomohiro Kitahara, Masaaki Miyo, Yoshihiro Kano, Shinpei Nishikawa, Takahito Fukusumi, Yusuke Takahashi, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Masakazu Ikenaga, Takeshi Kato, Kohei Murata, John M. Carethers, Hirofumi Yamamoto, Yuichiro Doki, and Masaki Mori

5287 Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer



L. Tiffany Lyle, Paul R. Lockman, Chris E. Adkins, Afroz Shareef Mohammad, Emily Sechrest, Emily Hua, Diane Palmieri, David J. Liewehr, Seth M. Steinberg, Wojciech Kloc, Ewa Izycka-Swieszewska, Renata Duchnowska, Naema Nayyar, Priscilla K. Brastianos, Patricia S. Steeg, and Brunilde Gril

5300 Ultrastructural Insights into the Biological Significance of Persisting DNA Damage Foci after Low Doses of Ionizing Radiation

Yvonne Lorat, Stefanie Schanz, and Claudia E. Rube

5312 BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas

Aleksandra Olow, Sabine Mueller, Xiaodong Yang, Rintaro Hashizume, Justin Meyerowitz, William Weiss, Adam C. Resnick, Angela J. Waanders, Lukas J.A. Stalpers, Mitchel S. Berger, Nalin Gupta, C. David James, Claudia K. Petritsch, and Daphne A. Haas-Kogan

5322 Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer

Paola Francica, Lluís Nisa, Daniel M. Aebbersold, Rupert Langer, Friedhelm Bladt, Andree Blaukat, Deborah Stroka, María Rodríguez Martínez, Yitzhak Zimmer, and Michaela Medová

BIOLOGY OF HUMAN TUMORS

5337 Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis

Feng Geng, Xiang Cheng, Xiaoning Wu, Ji Young Yoo, Chunming Cheng, Jeffrey Yunhua Guo, Xiaokui Mo, Peng Ru, Brian Hurwitz, Sung-Hak Kim, Jose Otero, Vinay Puduvalli, Etienne Lefai, Jianjie Ma, Ichiro Nakano, Craig Horbinski, Balveen Kaur, Arnab Chakravarti, and Deliang Guo

5349 Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance

Hanwei Zhang, Kris Prado, Kelvin X. Zhang, Elizabeth M. Peek, Jane Lee, Xiaoyan Wang, Jiaoti Huang, Gang Li, Matteo Pellegrini, and Arnold I. Chin

Table of Contents

- 5362** Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Rekha Gyanchandani, Yan Lin, Hui-Min Lin, Kristine Cooper, Daniel P. Normolle, Adam Brufsky, Michael Fastuca, Whitney Crosson, Steffi Oesterreich, Nancy E. Davidson, Rohit Bhargava, David J. Dabbs, and Adrian V. Lee

- 5370** PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of *EGFR* Mutation
De-Wei Wu, Tzu-Chin Wu, Chih-Yi Chen, and Huei Lee

- 5383** Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
Zhang Xiao Ying, Meiyan Jin, Luke F. Peterson, Denzil Bernard, Kamlai Saiya-Cork, Mehmet Yildiz, Shaomeng Wang, Mark S. Kaminski, Alfred E. Chang, Daniel J. Klionsky, and Sami N. Malek




AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of a head and neck xenograft tumor in mice. Hematoxylin and eosin staining shows characteristic features of head and neck squamous cell carcinoma evident by hyperchromatism, pleomorphism, loss of polarity, and increased mitotic activity. For details, see the article by Yoo and colleagues on page 5265 of this issue.



Clinical Cancer Research

22 (21)

Clin Cancer Res 2016;22:5159-5393.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/21>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/21>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.